This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development, it states. Technological capabilities at the site include cell-based assays,
immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry, and proteomics. The site is equipped to handle small molecules, as well as complex therapeutic modalities, including peptides, antibodies, oligonucleotides and cell and gene therapies.

“Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” says Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “By investing in advanced capabilities and strategic locations, such as Gothenburg, we are helping our customers in Europe and globally accelerate innovation and bring new therapies to patients faster.”

The new lab in Gothenburg reinforces the company’s long term commitment to the Swedish life sciences ecosystem and continued growth as a major employer and investor in the region, it states.